Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Annalisa Schirinzi, Angela Pia Cazzolla, Elisa Mascolo, Giuseppe Palmieri, ">Francesco Pesce, ">Loreto Gesualdo, ">Luigi Santacroce, ">Andrea Ballini *, Roberto Lovero and Francesca Di Serio

DOI: 10.2174/1871530320666200807121050

DownloadDownload PDF Flyer Cite As
Determination of the Upper Reference Limit of Human Epididymis Secretory Protein 4 (HE4) in Healthy Male Individuals and Correlation with Renal and Fertility Markers

Page: [912 - 918] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: Elevated human epididymis secretory protein 4 (HE4) serum levels have been widely investigated in patients with ovarian cancer. However, high levels of HE4 can be also found in other tumors and in renal fibrosis. To date, the HE4 assay manufacturer features the reference value only for the female pre- and post-menopausal population. The aim of this study was to determine the upper reference limit (URL) of HE4 in a well-defined and large cohort of healthy male individuals and investigate potential factors influencing HE4 levels in healthy subjects.

Methods: The study included 307 Italian healthy male individuals. HE4 was measured using a chemiluminescent assay (Abbott Laboratories, Wiesbaden, Germany). The URL was calculated using the non-parametric percentile method. Differences in HE4 concentrations according to age, estimated glomerular filtration rate (eGFR), free and bioavailable testosterone were also evaluated.

Results: The 97.5th percentile URL of serum HE4 in our study population was 57 pmol/L (90% CI). After stratifying subjects according to age, we found that the URL of HE4 was higher in older (> 50 years) than in younger subjects (18-30 years old), and overlapping with the URL in males from 31 to 50 years old (P=4.769e-16, r=0.44). A strong negative correlation between HE4 and eGFR was observed (P=8.412e-12, r=-0.38). Moreover, a statistically significant negative correlation was also found between HE4 and free and bioavailable testosterone.

Conclusion: This study determined the URL of HE4 in a large cohort of healthy male subjects. Our findings indicate that the HE4 age-dependent differences in males need to be taken into account. The definition of the HE4 URL in males and the correlation observed with eGFR and testosterone should foster the clinical use of HE4 beyond gynecologic cancer.

Keywords: Human epididymis secretory protein 4 (HE4), free and bioavailable testosterone, clinical biochemistry and clinical molecular biology, estimated glomerular filtration rate (eGFR), translational medicine, upper reference limit (URL), laboratory medicine.

Graphical Abstract

[1]
Kirchhoff, C.; Habben, I.; Ivell, R.; Krull, N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod., 1991, 45(2), 350-357.
[http://dx.doi.org/10.1095/biolreprod45.2.350] [PMID: 1686187]
[2]
Cicinelli, E.; Ballini, A.; Marinaccio, M.; Poliseno, A.; Coscia, M.F.; Monno, R.; De Vito, D. Microbiological findings in endometrial specimen: our experience. Arch. Gynecol. Obstet., 2012, 285(5), 1325-1329.
[http://dx.doi.org/10.1007/s00404-011-2138-9] [PMID: 22113463]
[3]
Bingle, L.; Singleton, V.; Bingle, C.D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene, 2002, 21(17), 2768-2773.
[http://dx.doi.org/10.1038/sj.onc.1205363] [PMID: 11965550]
[4]
Drapkin, R.; von Horsten, H-H.; Lin, Y.; Mok, S.C.; Crum, C.P.; Welch, W.R.; Hecht, J.L. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res., 2005, 65(6), 2162-2169.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-3924] [PMID: 15781627]
[5]
Hada, A.; Han, L.P.; Chen, Y.; Hu, Q.H.; Yuan, Y.; Liu, L. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses. J. Ovarian Res., 2020, 13(1), 46.
[http://dx.doi.org/10.1186/s13048-020-00643-6] [PMID: 32334618]
[6]
Georgakopoulos, P.; Mehmood, S.; Akalin, A.; Shroyer, K.R. Immunohistochemical localization of HE4 in benign, borderline, and malignant lesions of the ovary. Int. J. Gynecol. Pathol., 2012, 31(6), 517-523.
[http://dx.doi.org/10.1097/PGP.0b013e31824fe269] [PMID: 23018214]
[7]
Ross, D.T.; Scherf, U.; Eisen, M.B.; Perou, C.M.; Rees, C.; Spellman, P.; Iyer, V.; Jeffrey, S.S.; Van de Rijn, M.; Waltham, M.; Pergamenschikov, A.; Lee, J.C.; Lashkari, D.; Shalon, D.; Myers, T.G.; Weinstein, J.N.; Botstein, D.; Brown, P.O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet., 2000, 24(3), 227-235.
[http://dx.doi.org/10.1038/73432] [PMID: 10700174]
[8]
Escudero, J.M.; Auge, J.M.; Filella, X.; Torne, A.; Pahisa, J.; Molina, R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin. Chem., 2011, 57(11), 1534-1544.
[http://dx.doi.org/10.1373/clinchem.2010.157073] [PMID: 21933899]
[9]
FDA U.S. Food and Drug Administration. Available at: www.fda.gov
[10]
Galgano, M.T.; Hampton, G.M.; Frierson Jr, H.F. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod. Pathol., 2006, 19(6), 847-853.
[http://dx.doi.org/10.1038/modpathol.3800612] [PMID: 16607372]
[11]
Bingle, L.; Cross, S.S.; High, A.S.; Wallace, W.A.; Rassl, D.; Yuan, G.; Hellstrom, I.; Campos, M.A.; Bingle, C.D. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir. Res., 2006, 7, 61.
[http://dx.doi.org/10.1186/1465-9921-7-61] [PMID: 16600032]
[12]
Yamashita, S.; Tokuishi, K.; Hashimoto, T.; Moroga, T.; Kamei, M.; Ono, K.; Miyawaki, M.; Takeno, S.; Chujo, M.; Yamamoto, S.; Kawahara, K. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol., 2011, 32(2), 265-271.
[http://dx.doi.org/10.1007/s13277-010-0118-5] [PMID: 20953751]
[13]
Elsammak, M.Y.; Attia, A.; Hassan, H.A.; Zaytoun, T.M.; Shorman, M.; Suleman, M. Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusion. Tumour Biol., 2012, 33(5), 1701-1707.
[http://dx.doi.org/10.1007/s13277-012-0427-y] [PMID: 22684816]
[14]
Iwahori, K.; Suzuki, H.; Kishi, Y.; Fujii, Y.; Uehara, R.; Okamoto, N.; Kobayashi, M.; Hirashima, T.; Kawase, I.; Naka, T. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol., 2012, 33(4), 1141-1149.
[http://dx.doi.org/10.1007/s13277-012-0356-9] [PMID: 22373583]
[15]
Mo, D.; He, F. Serum human epididymis secretory protein 4 (HE4) is a potential prognostic biomarker in non-small cell lung cancer. Clin. Lab., 2018, 64(9), 1421-1428.
[http://dx.doi.org/10.7754/Clin.Lab.2018.180222] [PMID: 30274019]
[16]
Karlsen, N.S.; Karlsen, M.A.; Høgdall, C.K.; Høgdall, E.V. HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review. Cancer Epidemiol. Biomarkers Prev., 2014, 23(11), 2285-2295.
[http://dx.doi.org/10.1158/1055-9965.EPI-14-0447] [PMID: 25169975]
[17]
Jiang, Y.; Wang, C.; Lv, B.; Ma, G.; Wang, L. Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer. Int. J. Clin. Exp. Med., 2014, 7(12), 5568-5572.
[PMID: 25664073]
[18]
LeBleu, V.S.; Teng, Y.; O’Connell, J.T.; Charytan, D.; Müller, G.A.; Müller, C.A.; Sugimoto, H.; Kalluri, R. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat. Med., 2013, 19(2), 227-231.
[http://dx.doi.org/10.1038/nm.2989] [PMID: 23353556]
[19]
Wan, J.; Wang, Y.; Cai, G.; Liang, J.; Yue, C.; Wang, F.; Song, J.; Wang, J.; Liu, M.; Luo, J.; Li, L. Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease. Oncotarget, 2016, 7(42), 67748-67759.
[http://dx.doi.org/10.18632/oncotarget.11682] [PMID: 27589683]
[20]
Allison, S.J. Fibrosis: HE4—a biomarker and target in renal fibrosis. Nat. Rev. Nephrol., 2013, 9, 124.
[http://dx.doi.org/10.1038/nrneph.2013.2]
[21]
Nagy, B., Jr; Krasznai, Z.T.; Balla, H.; Csobán, M.; Antal-Szalmás, P.; Hernádi, Z.; Kappelmayer, J. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann. Clin. Biochem., 2012, 49(Pt 4), 377-380.
[http://dx.doi.org/10.1258/acb.2011.011258] [PMID: 22688735]
[22]
Stevens, P.E.; Levin, A. Kidney disease: improving global outcomes chronic kidney disease guideline development work group members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med., 2013, 158(11), 825-830.
[http://dx.doi.org/10.7326/0003-4819-158-11-201306040-00007] [PMID: 23732715]
[23]
National Committee for Clinical Laboratory Standard (NCCLS). Demonstration of Performance for Precision and Accuracy; Approved Guideline. NCCLS document EP15-A (ISBN 1-56238-451-1); NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2001.
[24]
Vermeulen, A.; Verdonck, L.; Kaufman, J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab., 1999, 84(10), 3666-3672.
[http://dx.doi.org/10.1210/jcem.84.10.6079] [PMID: 10523012]
[25]
Clinical Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory - Approved guideline, Third; CLSI document C28 - A3c. Wayne, PA: CLSI, 2008.
[26]
Bolstad, N.; Øijordsbakken, M.; Nustad, K.; Bjerner, J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol., 2012, 33(1), 141-148.
[http://dx.doi.org/10.1007/s13277-011-0256-4] [PMID: 22105734]
[27]
Luo, J.; Wang, F.; Wan, J.; Ye, Z.; Huang, C.; Cai, Y.; Liu, M.; Wu, B.Q.; Li, L. Serum human epididymis secretory protein 4 as a potential biomarker of renal fibrosis in kidney transplantation recipients. Clin. Chim. Acta, 2018, 483, 216-221.
[http://dx.doi.org/10.1016/j.cca.2018.05.006] [PMID: 29738696]
[28]
Lamy, P.J.; Plassot, C.; Pujol, J.L. Serum HE4: an independent prognostic factor in non-small cell lung cancer. PLoS One, 2015, 10(6)e0128836
[http://dx.doi.org/10.1371/journal.pone.0128836] [PMID: 26030627]
[29]
Piek, A.; Meijers, W.C.; Schroten, N.F.; Gansevoort, R.T.; de Boer, R.A.; Silljé, H.H.W. HE4 serum levels are associated with heart failure severity in patients with chronic heart failure. J. Card. Fail., 2017, 23(1), 12-19.
[http://dx.doi.org/10.1016/j.cardfail.2016.05.002] [PMID: 27224553]
[30]
Yang, Z.; Zhang, Z.; Qin, B.; Wu, P.; Zhong, R.; Zhou, L.; Liang, Y. Human epididymis protein 4: a novel biomarker for lupus nephritis and chronic kidney disease in systemic lupus erythematosus. J. Clin. Lab. Anal., 2016, 30(6), 897-904.
[http://dx.doi.org/10.1002/jcla.21954] [PMID: 27075413]
[31]
Yang, J.; Sa, M.; Huang, M.; Yang, J.; Xiang, Z.; Liu, B.; Tang, A. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay. Clin. Biochem., 2013, 46(16-17), 1705-1708.
[http://dx.doi.org/10.1016/j.clinbiochem.2013.08.019] [PMID: 24012857]
[32]
Di Serio, F.; Lovero, R.; D’Agostino, D.; Nisi, L.; Miragliotta, G.; Contino, R.; Man, A.; Ciccone, M.M.; Santacroce, L. Evaluation of procalcitonin, Vitamin D and C-reactive protein levels in septic patients with positive emocoltures. Our preliminary experience. Acta Med. Mediter., 2016, 32, 1911-1914.
[http://dx.doi.org/10.19193/0393-6384_2016_6_182]
[33]
Foti, C.; Romita, P.; Rigano, L.; Zimerson, E.; Sicilia, M.; Ballini, A.; Ghizzoni, O.; Antelmi, A.; Angelini, G.; Bonamonte, D.; Bruze, M. Isobornyl acrylate: an impurity in alkyl glucosides. Cutan. Ocul. Toxicol., 2016, 35(2), 115-119.
[http://dx.doi.org/10.3109/15569527.2015.1055495] [PMID: 26095233]